Results 161 to 170 of about 14,066,519 (402)

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Pragmatic clinical trials

Complementary Therapies in Medicine, 2004
Both pragmatic and explanatory randomised controlled trials have a useful role to play in the evaluation of health care interventions. In this descriptive article, the key steps in conducting a pragmatic trial are described. The strengths and limitations of pragmatic trials are also discussed.
openaire   +2 more sources

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

Views of research ethics committee members on end-of-participation communications for trial participants who stop taking part: a cross-sectional survey study

Trials
Background Giving information to trial participants who stop taking part could support them through what can be a difficult process. We previously developed guidance around the ethical acceptability of such information provision, and about how trialists ...
William J. Cragg, Liam Bishop, Rachael Gilberts, Michael Gregg, Mary Mancini, Clara Martins de Barros   +5 more
doaj   +1 more source

Regulating Access to Developmental Drugs for Terminally Ill Patients: Abigail Alliance v FDA [PDF]

This amicus brief was filed in support of the Abigail Alliance for Better Access to Developmental Drugs in their lawsuit to force the Food and Drug Administration to provide patient access to drugs for cancer and other life-threatening illnesses after ...
Calfee, John E., Klein, Daniel B., Peltzman, Sam, Tabarrok, Alex, Zycher, Benjamin   +4 more
core   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Endoscopic lavage after intraventricular haemorrhage in neonates in the UK (ENLIVEN-UK): study protocol for a national randomised-controlled trial

Trials
Background Intraventricular haemorrhage (IVH) is a common and severe complication of preterm birth, affecting nearly 500 neonates annually in the UK.
Saniya Mediratta, Aswin Chari, Cheryl Battersby, Patrick Bauserman, Emilia Caverly, William Dawes, Hakim-Moulay Dehbi, Andrew Embleton-Thirsk, Laurence Galland, Gregory James, Sally Jary, Charlotte Kelham, Alyson MacNeil, Sue Massingham, Neil Marlow, Amalia Ndoutoumou, Monica Panca, Victoria Pittordou, Cristine Sortica da Costa, Andrew Whitelaw, Conor Mallucci, Kristian Aquilina   +21 more
doaj   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

, 2022
Xue Hua, Kevin Church, William Walker, Philippe L’Hostis, Geoffrey Viardot, Philippe Danjou, Suzanne Hendrix, Hans J. Moebius   +7 more
openalex   +2 more sources

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Designing e-consent protocols for pragmatic clinical trials: case studies from a UKCRC clinical trials unit

Trials
Background Interest in and use of electronic consent (e-consent) in the conduct of academic clinical trials has increased since the COVID-19 pandemic.
M. Hammond, P. Ashford, J. High, L. V. Clark, G. Howard, M. Jones, S. Stirling, C. West, on behalf of the Norwich CTU Methodology Group   +8 more
doaj   +1 more source